Therapure Biopharma Awarded US Government Contract
News Jun 20, 2013
Therapure Biopharma Inc. has announced the company will participate as a subcontractor for DynPort Vaccine Company LLC (DVC), a CSC company, that was awarded a US cost-plus-fixed-fee contract with a maximum value of $157.3 million (prime contract number W911QY-13-C-0056) by the US Department of Defense (DoD) to support the development of a prophylactic countermeasure to prevent the effects of organophosphorus nerve agent poisoning.
Therapure’s subcontract under the above prime contract includes process optimization as well as manufacture of all clinical and nonclinical materials (drug product) to support DVC’s contract to develop, test and obtain the US Food and Drug Administration (FDA) approval for human plasma-derived butyrylcholinesterase (HuBChE), a blood plasma protein that binds and inactivates nerve agents.
Mr. Nick Green, Therapure’s President and Chief Executive Officer, said: “We are delighted to partner with DVC to develop and manufacture medical counter measures for the US Department of Defense as part of a defense strategy against a wide range of nerve gases. Therapure successfully completed a rigorous selection and approval process to serve as the manufacturing subcontractor under the prime contract, which is a testament to the Company’s standards and capabilities in biomanufacturing. It is an honor to be part of this very critical initiative to protect US Servicemen and women.”
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019